Golimumab
- PMID: 20065639
- PMCID: PMC2759491
- DOI: 10.4161/mabs.1.5.9286
Golimumab
Abstract
Golimumab, a human anti-TNFalpha IgG1kappa monoclonal antibody, was approved in the US and Canada in April 2009 as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and is undergoing regulatory review in the EU for these indications. The product was developed by Centocor and Janssen Pharmaceutical KK (Johnson & Johnson subsidiaries), in collaboration with Schering-Plough and Mitsubishi Tanabe Pharma. Golimumab faces numerous protein therapeutic competitors on the market, but, as the first patient-administered, once-monthly dosed anti-TNFalpha drug, it will likely be an attractive option for patients.
Figures
Similar articles
-
Golimumab, a fully human monoclonal antibody against TNFalpha.Curr Opin Mol Ther. 2008 Aug;10(4):393-406. Curr Opin Mol Ther. 2008. PMID: 18683105
-
Golimumab (simponi) for inflammatory arthritis.Med Lett Drugs Ther. 2009 Jul 13;51(1316):55-6. Med Lett Drugs Ther. 2009. PMID: 19590489 No abstract available.
-
Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.BioDrugs. 2009;23(2):125-35. doi: 10.2165/00063030-200923020-00005. BioDrugs. 2009. PMID: 19489653 Review.
-
Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.Clin Ther. 2010 Sep;32(10):1681-703. doi: 10.1016/j.clinthera.2010.09.003. Clin Ther. 2010. PMID: 21194591 Review.
-
Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.Isr Med Assoc J. 2012 Jun;14(6):390-4. Isr Med Assoc J. 2012. PMID: 22891404 Review.
Cited by
-
Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.JAMA Intern Med. 2019 May 1;179(5):713-716. doi: 10.1001/jamainternmed.2018.7656. JAMA Intern Med. 2019. PMID: 30776053 Free PMC article.
-
Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies-in silico analysis.J Genet Eng Biotechnol. 2022 Jan 10;20(1):7. doi: 10.1186/s43141-021-00288-y. J Genet Eng Biotechnol. 2022. PMID: 35006391 Free PMC article.
-
Therapeutic Strategies Targeting Pancreatic Islet β-Cell Proliferation, Regeneration, and Replacement.Endocrinology. 2022 Nov 14;164(1):bqac193. doi: 10.1210/endocr/bqac193. Endocrinology. 2022. PMID: 36412119 Free PMC article.
-
Epipharyngeal Abrasive Therapy (EAT) Reduces the mRNA Expression of Major Proinflammatory Cytokine IL-6 in Chronic Epipharyngitis.Int J Mol Sci. 2022 Aug 16;23(16):9205. doi: 10.3390/ijms23169205. Int J Mol Sci. 2022. PMID: 36012469 Free PMC article.
-
Two cases of Erythrodermic psoriasis treated with Golimumab.Ann Med Surg (Lond). 2022 Jun 8;78:103961. doi: 10.1016/j.amsu.2022.103961. eCollection 2022 Jun. Ann Med Surg (Lond). 2022. PMID: 35734731 Free PMC article.
References
-
- Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis mechanism of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279. - PubMed
-
- Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:15–25. - PubMed
-
- Shealy D, Cai A, Lacy E, Nesspor T, Staquet K, Johns L, et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNFα. Ann Rheum Dis. 2007;66:151. - PubMed
-
- Martin PL, Cornacoff J, Prabhakar U, Lohr T, Treacy G, Sutherland JE, et al. Preclinical safety and immune-modulating effects of therapeutic monoclonal antibodies to interleukin-6 and tumor necrosis factor-α in cynomolgus macaques. J Immunotoxicol. 2004;1:131–139. - PubMed
-
- Martin PL, Oneda S, Treacy G. Effects of an anti-TNFα monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system. Am J Reprod Immunol. 2007;58:138–149. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous